Titre : Jumonji Domain-Containing Histone Demethylases

Jumonji Domain-Containing Histone Demethylases : Questions médicales fréquentes

Termes MeSH sélectionnés :

Visual Pathways
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Jumonji Domain-Containing Histone Demethylases : Questions médicales les plus fréquentes", "headline": "Jumonji Domain-Containing Histone Demethylases : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Jumonji Domain-Containing Histone Demethylases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-10", "dateModified": "2025-04-06", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Jumonji Domain-Containing Histone Demethylases" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Dioxygenases", "url": "https://questionsmedicales.fr/mesh/D049308", "about": { "@type": "MedicalCondition", "name": "Dioxygenases", "code": { "@type": "MedicalCode", "code": "D049308", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.682.690.416" } } }, "about": { "@type": "MedicalCondition", "name": "Jumonji Domain-Containing Histone Demethylases", "alternateName": "Jumonji Domain-Containing Histone Demethylases", "code": { "@type": "MedicalCode", "code": "D056484", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Danica Galonić Fujimori", "url": "https://questionsmedicales.fr/author/Danica%20Galoni%C4%87%20Fujimori", "affiliation": { "@type": "Organization", "name": "Department of Cellular and Molecular Pharmacology, University of California San Francisco; San Francisco, CA 94158, USA; Department of Pharmaceutical Chemistry, University of California San Francisco; San Francisco, CA 94158, USA; Quantitative Biosciences Institute (QBI), University of California San Francisco; San Francisco, CA 94158, USA. Electronic address: danica.fujimori@ucsf.edu." } }, { "@type": "Person", "name": "James E Longbotham", "url": "https://questionsmedicales.fr/author/James%20E%20Longbotham", "affiliation": { "@type": "Organization", "name": "Department of Cellular and Molecular Pharmacology, University of California San Francisco, 600 16th Street, Genentech Hall, San Francisco, California 94158, United States." } }, { "@type": "Person", "name": "Feng Li", "url": "https://questionsmedicales.fr/author/Feng%20Li", "affiliation": { "@type": "Organization", "name": "Department of Cell Biology, Key Laboratory of Cell Biology, National Health Commission of the PRC, Shenyang, China." } }, { "@type": "Person", "name": "Christopher J Schofield", "url": "https://questionsmedicales.fr/author/Christopher%20J%20Schofield", "affiliation": { "@type": "Organization", "name": "Chemistry Research Laboratory , University of Oxford , 12 Mansfield Road , Oxford OX1 3TA , United Kingdom." } }, { "@type": "Person", "name": "Anthony Tumber", "url": "https://questionsmedicales.fr/author/Anthony%20Tumber", "affiliation": { "@type": "Organization", "name": "Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford 12 Mansfield Road OX1 3TA Oxford UK christopher.schofield@chem.ox.ac.uk lennart.brewitz@chem.ox.ac.uk." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Category-specific and category-general neural codes of recognition memory in the ventral visual pathway.", "datePublished": "2023-04-29", "url": "https://questionsmedicales.fr/article/37207411", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.cortex.2023.04.004" } }, { "@type": "ScholarlyArticle", "name": "The features analysis of hemoglobin expression on visual information transmission pathway in early stage of Alzheimer's disease.", "datePublished": "2024-07-08", "url": "https://questionsmedicales.fr/article/38972885", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-024-64099-0" } }, { "@type": "ScholarlyArticle", "name": "Disrupted third visual pathway function in schizophrenia: Evidence from real and implied motion processing.", "datePublished": "2024-01-26", "url": "https://questionsmedicales.fr/article/38309185", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.nicl.2024.103570" } }, { "@type": "ScholarlyArticle", "name": "Causal effect of COVID-19 on optic nerve and visual pathway disorders: genetic evidence of lung-brain axis.", "datePublished": "2024-07-16", "url": "https://questionsmedicales.fr/article/39081310", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2024.1440262" } }, { "@type": "ScholarlyArticle", "name": "Retinal structure and visual pathway function at school age in children born extremely preterm: a population-based study.", "datePublished": "2023-07-01", "url": "https://questionsmedicales.fr/article/37393251", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12886-023-03055-4" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Enzymes et coenzymes", "item": "https://questionsmedicales.fr/mesh/D045762" }, { "@type": "ListItem", "position": 3, "name": "Enzymes", "item": "https://questionsmedicales.fr/mesh/D004798" }, { "@type": "ListItem", "position": 4, "name": "Oxidoreductases", "item": "https://questionsmedicales.fr/mesh/D010088" }, { "@type": "ListItem", "position": 5, "name": "Oxygénases", "item": "https://questionsmedicales.fr/mesh/D010105" }, { "@type": "ListItem", "position": 6, "name": "Dioxygenases", "item": "https://questionsmedicales.fr/mesh/D049308" }, { "@type": "ListItem", "position": 7, "name": "Jumonji Domain-Containing Histone Demethylases", "item": "https://questionsmedicales.fr/mesh/D056484" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Jumonji Domain-Containing Histone Demethylases - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Jumonji Domain-Containing Histone Demethylases", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-14", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Jumonji Domain-Containing Histone Demethylases", "description": "Comment diagnostiquer une dysfonction des Jumonji ?\nQuels marqueurs biologiques sont associés aux Jumonji ?\nLes biopsies sont-elles utiles pour le diagnostic ?\nQuels tests sanguins sont recommandés ?\nY a-t-il des tests d'imagerie pour ces enzymes ?", "url": "https://questionsmedicales.fr/mesh/D056484?mesh_terms=Visual+Pathways&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Jumonji Domain-Containing Histone Demethylases", "description": "Quels symptômes sont liés aux anomalies des Jumonji ?\nLes troubles neurologiques sont-ils associés ?\nY a-t-il des symptômes cutanés associés ?\nLes symptômes varient-ils selon le type de Jumonji ?\nLes symptômes sont-ils réversibles ?", "url": "https://questionsmedicales.fr/mesh/D056484?mesh_terms=Visual+Pathways&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Jumonji Domain-Containing Histone Demethylases", "description": "Peut-on prévenir les dysfonctionnements des Jumonji ?\nLes tests génétiques peuvent-ils aider à la prévention ?\nY a-t-il des vaccins pour prévenir ces dysfonctionnements ?\nL'éducation génétique est-elle importante ?\nLes conseils diététiques peuvent-ils aider ?", "url": "https://questionsmedicales.fr/mesh/D056484?mesh_terms=Visual+Pathways&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Jumonji Domain-Containing Histone Demethylases", "description": "Quels traitements sont disponibles pour les dysfonctionnements des Jumonji ?\nLes médicaments peuvent-ils cibler les Jumonji ?\nY a-t-il des traitements naturels recommandés ?\nLes traitements sont-ils personnalisés ?\nLes thérapies combinées sont-elles efficaces ?", "url": "https://questionsmedicales.fr/mesh/D056484?mesh_terms=Visual+Pathways&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Jumonji Domain-Containing Histone Demethylases", "description": "Quelles complications peuvent survenir avec les dysfonctionnements des Jumonji ?\nLes complications sont-elles graves ?\nY a-t-il des complications à long terme ?\nLes complications sont-elles réversibles ?\nLes complications varient-elles selon le type de Jumonji ?", "url": "https://questionsmedicales.fr/mesh/D056484?mesh_terms=Visual+Pathways&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Jumonji Domain-Containing Histone Demethylases", "description": "Quels sont les facteurs de risque pour les dysfonctionnements des Jumonji ?\nL'âge est-il un facteur de risque ?\nLes antécédents familiaux jouent-ils un rôle ?\nL'exposition à des toxines est-elle un facteur ?\nLe mode de vie influence-t-il le risque ?", "url": "https://questionsmedicales.fr/mesh/D056484?mesh_terms=Visual+Pathways&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dysfonction des Jumonji ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses d'expression génique peuvent être utilisés." } }, { "@type": "Question", "name": "Quels marqueurs biologiques sont associés aux Jumonji ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les niveaux de méthylation des histones et l'expression des gènes sont des marqueurs clés." } }, { "@type": "Question", "name": "Les biopsies sont-elles utiles pour le diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les biopsies peuvent aider à évaluer l'expression des Jumonji dans les tissus." } }, { "@type": "Question", "name": "Quels tests sanguins sont recommandés ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des tests pour mesurer les niveaux de protéines associées aux Jumonji peuvent être effectués." } }, { "@type": "Question", "name": "Y a-t-il des tests d'imagerie pour ces enzymes ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Non, l'imagerie ne permet pas de diagnostiquer directement les Jumonji." } }, { "@type": "Question", "name": "Quels symptômes sont liés aux anomalies des Jumonji ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles de croissance, des anomalies développementales et des cancers peuvent survenir." } }, { "@type": "Question", "name": "Les troubles neurologiques sont-ils associés ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des dysfonctionnements neurologiques peuvent être liés à des mutations des Jumonji." } }, { "@type": "Question", "name": "Y a-t-il des symptômes cutanés associés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Certaines anomalies cutanées peuvent être observées, notamment dans des syndromes spécifiques." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon le type de Jumonji ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, différents types de Jumonji peuvent entraîner des symptômes variés selon leur fonction." } }, { "@type": "Question", "name": "Les symptômes sont-ils réversibles ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Cela dépend de la gravité et de la nature de la dysfonction des Jumonji." } }, { "@type": "Question", "name": "Peut-on prévenir les dysfonctionnements des Jumonji ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est difficile, mais un mode de vie sain peut réduire les risques." } }, { "@type": "Question", "name": "Les tests génétiques peuvent-ils aider à la prévention ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tests génétiques peuvent identifier les individus à risque de dysfonctionnements." } }, { "@type": "Question", "name": "Y a-t-il des vaccins pour prévenir ces dysfonctionnements ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Non, il n'existe pas de vaccins spécifiques pour prévenir les dysfonctionnements des Jumonji." } }, { "@type": "Question", "name": "L'éducation génétique est-elle importante ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'éducation sur les risques génétiques peut aider à la prévention et à la détection précoce." } }, { "@type": "Question", "name": "Les conseils diététiques peuvent-ils aider ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée peut soutenir la santé cellulaire, mais ne prévient pas directement." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour les dysfonctionnements des Jumonji ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies géniques et des inhibiteurs spécifiques sont en cours d'étude." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils cibler les Jumonji ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments expérimentaux ciblent les Jumonji pour traiter des cancers." } }, { "@type": "Question", "name": "Y a-t-il des traitements naturels recommandés ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des approches nutritionnelles et phytothérapeutiques sont explorées, mais peu prouvées." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements peuvent être adaptés en fonction des mutations spécifiques des Jumonji." } }, { "@type": "Question", "name": "Les thérapies combinées sont-elles efficaces ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des études montrent que les thérapies combinées peuvent améliorer les résultats cliniques." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec les dysfonctionnements des Jumonji ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des cancers, des troubles métaboliques et des anomalies développementales peuvent survenir." } }, { "@type": "Question", "name": "Les complications sont-elles graves ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines complications peuvent être potentiellement mortelles si non traitées." } }, { "@type": "Question", "name": "Y a-t-il des complications à long terme ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des complications chroniques peuvent se développer, affectant la qualité de vie." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles." } }, { "@type": "Question", "name": "Les complications varient-elles selon le type de Jumonji ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent varier en fonction du type de Jumonji impliqué." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les dysfonctionnements des Jumonji ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs génétiques, environnementaux et liés au mode de vie peuvent influencer le risque." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains dysfonctionnements des Jumonji sont plus fréquents avec l'âge." } }, { "@type": "Question", "name": "Les antécédents familiaux jouent-ils un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de maladies génétiques augmentent le risque." } }, { "@type": "Question", "name": "L'exposition à des toxines est-elle un facteur ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à certaines toxines peut augmenter le risque de dysfonctionnements." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie malsain peut accroître le risque de dysfonctionnements des Jumonji." } } ] } ] }

Sources (10000 au total)

Causal effect of COVID-19 on optic nerve and visual pathway disorders: genetic evidence of lung-brain axis.

To investigate the potential causal association between COVID-19 exposure and optic nerve and visual pathway disorders through a two-sample bidirectional Mendelian randomization (MR) analysis, and to ... This MR analysis utilized publicly accessible summary-level data from genome-wide association studies on COVID-19 (n=158,783) and optic nerve and visual pathway diseases (n=412,181), primarily involvi... In the forward analysis, the inverse-variance weighted method identified a significant causal effect of COVID-19 on optic nerve and visual pathway disorders (odds ratio = 1.697, 95% confidence interva... Our findings suggest that COVID-19 exposure may increase the risk of developing optic nerve and visual pathway disorders, supporting the lung-brain axis hypothesis. These results underscore the import...

Retinal structure and visual pathway function at school age in children born extremely preterm: a population-based study.

Children born extremely preterm (gestational age < 28 weeks) show reduced visual function even without any cerebral or ophthalmological neonatal diagnosis. In this study, we aimed to assess the retina... All children born extremely preterm from 2006-2011 (n = 65) in Central Norway were invited to participate. Thirty-six children (55%) with a median age of 13 years (range = 10-16) were examined with OC... Participants displayed abnormal retinal structure and P100 latencies (≥ 2 SD) compared to reference populations. Moreover, there was a negative correlation between P100 latency in large checks and RNF... Children born extremely preterm without preterm brain injury sequelae have signs of persistent immaturity of retinal vasculature and neuroretinal layers. Thinner neuroretinal layers are associated wit...

Age-related changes in the healthy adult visual pathway: evidence from diffusion tensor imaging with fixel-based analysis.

Fixel-based analysis (FBA) is a new method that overcomes the technical limitations of diffusion tensor imaging (DTI) by enabling the characterization of multiple fiber populations within a voxel, and... In this prospective cross-sectional study, brain DTI scans which were collected with more than six uniformly distributed gradient directions and higher b‑values (up to 2000 s/mm... Pearson's correlation analysis showed that DTI parameters of white matter (optic nerve, optic chiasma, optic tract, and optic radiation) in the optic pathway were correlated with age. FA values were n... FBA provides a useful method to assess age-related changes in the visual pathway, which is sensitive to diffusion. In addition, the b‑value influences DTI parameters and signal-to-noise ratio of the i...

Visual Pathway Involvement in NMDA Receptor Encephalitis: A Clinical, Optical Coherence Tomography, and 18-Fluorodeoxyglucose PET/CT Approach.

Anti-NMDA receptor (NMDAR) encephalitis patients have been reported to exhibit visual dysfunction without retinal thinning. The objective of our study was to examine the involvement of the visual path... In this cross-sectional study, patients diagnosed with anti-NMDAR encephalitis per consensus criteria underwent postrecovery visual acuity (VA) testing and optical coherence tomography (OCT) with auto... A total of 16 anti-NMDAR (32 eyes) and 32 HC (64 eyes) were included in the study. Anti-NMDAR exhibited lower low-contrast VA (2.5% contrast: -4.4 letters [95% CI; -8.5 to -0.3]; P = 0.04, 1.25% contr... Although the visual system seems to be involved in anti-NMDAR encephalitis, no retinal structural or occipital cortex functional abnormalities seem to be responsible for the visual dysfunction. When d...

Pediatric reference values of anterior visual pathway structures measured with axis-correction on high-resolution 3D T2 fast spin echo sequences.

The size of the anterior visual pathway (AVP) structures is affected by patient age and pathology. Normative data is useful when determining whether pathology is present. AVP structures do not respect... For each patient 32 measurements of AVP structures were obtained in 145 children (2 months - 18 years) with normal brain MR studies on high-resolution 3D T2w FSE images adjusted to the axis of each AV... Descriptive statistics were compiled in a reference table and prediction plots in relation to age, height, and body surface area (BSA) were obtained from the best overall performing statistical model,... Detailed charts of reference values for AVP structures as well as prediction plots in relation to age, height and BSA were established using axis-corrected measurements from the MPR of high-resolution...

Retinal Damage and Visual Network Reconfiguration Defines Visual Function Recovery in Optic Neuritis.

Recovery of vision after acute optic neuritis (AON) is critical to improving the quality of life of people with demyelinating diseases. The objective of the study was to prospectively assess the chang... We studied a prospective cohort of 88 consecutive patients with AON with 6-month follow-up using high and low-contrast (2.5%) visual acuity, color vision, retinal thickness from optical coherence tomo... We found that after 6 months, low-contrast vision and quality of vision remained moderately impaired. The thickness of the ganglion cell layer at baseline was a predictor of low-contrast vision 6 mont... The assessment of the visual pathway at baseline predicts permanent vision disability after AON, indicating that damage is produced early after disease onset and that it can be used for defining visio...